Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Illumina's interest expense for the
three
months ended in Mar. 2022 was $ -6 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2022 was $-49 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Illumina's Operating Income for the
three
months ended in Mar. 2022 was $ 184 Mil. Illumina's Interest Expense for the
three
months ended in Mar. 2022 was $ -6 Mil.
Illumina's Interest Coverage for the quarter that ended in Mar. 2022 was 30.67.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Illumina Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Illumina (NAS:ILMN) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Illumina's Interest Expense for the
three
months ended in Mar. 2022 was $-6 Mil. Its
Operating Income
for the
three
months ended in Mar. 2022 was $184 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Mar. 2022 was $2,044 Mil.
Illumina's Interest Coverage for the quarter that ended in Mar. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Illumina Business Description
Traded in Other Exchanges
Address
5200 Illumina Way, San Diego, CA, USA, 92122
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (76% of 2020 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 16% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.
Executives
| Flatley Jay T |
director |
9885 TOWNE CENTRE DR SAN DIEGO CA 92121 |
| Tousi Susan H |
officer: SVP Product Development |
5200 ILLUMINA WAY SAN DIEGO CA 92122 |
| Reeves Kathryne Gambrell |
officer: SVP, Chief Marketing Officer |
5200 ILLUMINA WAY SAN DIEGO CA 92122 |
| Goswami Joydeep |
officer: SVP Corp Business Development |
SUMITOMO FUDOSAN MITA TWIN BLDG EAST WING 4-2-8 SHIBAURA MINATO-KU TOKYO M0 1080023 |
| Dadswell Charles |
officer: SVP & General Counsel |
5200 ILLUMINA WAY SAN DIEGO CA 92122 |
| Desouza Francis A |
director, officer: President and CEO |
350 ELLIS STREET MOUNTAIN VIEW CA 94043 |
| Van Oene Mark |
officer: SVP Chief Commercial Officer |
5200 ILLUMINA WAY SAN DIEGO CA 92122 |
| Ragusa Robert P |
officer: SVP, Global Quality & Ops |
PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: RAGUSA ROBERT P a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;} |
| Mcginnis Karen K |
officer: VP, Chief Accounting Officer |
INSIGHT ENTERPRISES INC 1305 WEST AUTO DRIVE TEMPE AZ 85284 |
| Hoyt Aimee L |
officer: SVP, Chief People Officer |
5200 ILLUMINA WAY SAN DIEGO CA 92122 |
| Ronaghi Mostafa |
officer: SVP, Entrepreneurial Devlopmt |
9885 TOWNE CENTRE DRIVE SAN DIEGO CA 92121 |
| Aravanis Alexander |
officer: SVP, Chief Technology Officer |
5200 ILLUMINA WAY SAN DIEGO CA 92122 |
| Siegel Susan E |
director |
3000 SAND HILL ROAD BLDG 3 STE 290 MENLO PARK CA 94025 |
| Thompson John Wendell |
director |
C/O MICROSOFT CORPORATION ONE MICROSOFT WAY REDMOND WA 98053 |
| Epstein Robert S |
director |
PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: EPSTEIN ROBERT S a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;} |
Illumina Headlines
By Seekingalpha 2022-03-07
By Seekingalpha 2022-01-10
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
2.74(1.14%) Volume: 974,000 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:ILMN has been successfully added to your 
